Media coverage about Agile Therapeutics (NASDAQ:AGRX) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 44.8654274634958 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
AGRX has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 target price on shares of Agile Therapeutics in a research note on Friday, December 22nd. HC Wainwright set a $8.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 22nd. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research note on Thursday, December 28th. Janney Montgomery Scott lowered shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 28th. Finally, William Blair lowered shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.20.
Agile Therapeutics (NASDAQ AGRX) traded up $0.06 during trading on Friday, hitting $3.28. 259,782 shares of the stock were exchanged, compared to its average volume of 1,171,642. Agile Therapeutics has a one year low of $1.93 and a one year high of $5.60. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.10 and a current ratio of 4.10. The firm has a market cap of $110.08, a P/E ratio of -3.57 and a beta of 2.01.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03. analysts expect that Agile Therapeutics will post -0.97 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-agile-therapeutics-agrx-stock-price.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.